Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody‐mediated and/or T cell‐mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the bone marrow niche have now been recognized to be important. Treatment strategies are aimed at the restoration of platelet counts compatible with adequate hemostasis rather than achieving physiological platelet counts. The first line treatments focus on the inhibition of autoantibody production and platelet degradation, whereas second‐line treatments include immunosuppressive drugs, such as Rituximab, and splenectomy. Finally, thirdline treatments aim to stimulate platelet production by megakaryocytes. This review discusses the pathophysiology of ITP and how the different treatment modalities affect the pathogenic mechanisms.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2k6D8wH
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Purpose To test the effects of 4 weeks of unilateral low-load resistance training (LLRT), with and without blood flow restricti...
-
Abstract There are limited published data on the burden of rare cancers in the United States. By using data from the North American Associ...
-
Relativistic hydrodynamics has been quite successful in explaining the collective behaviour of the QCD matter produced in high energy heavy-...
-
36 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: quality...
-
by Claudia Zielke, Ondrej Kosik, Marie-Louise Ainalem, Alison Lovegrove, Anna Stradner, Lars Nilsson An extraction method for mixed-linkage...
-
The genital mucosa is a barrier that is constantly exposed to a variety of pathogens, allergens, and external stimuli. Although both allerge...
-
Abstract Purpose Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospective study,...
-
by Mark A. Valasek, Irene Thung, Esha Gollapalle, Alexey A. Hodkoff, Kaitlyn J. Kelly, Joel M. Baumgartner, Vera Vavinskaya, Grace Y. Lin, A...
-
The receptor tyrosine kinase KIT is an established oncogenic driver of tumor growth in certain tumor types, including gastrointestinal strom...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου